Boston Scientific (BSX) Expected to Announce Quarterly Earnings on Wednesday

Boston Scientific (NYSE:BSX) is expected to be announcing its earnings results before the market opens on Wednesday, April 23rd. Analysts expect the company to announce earnings of $0.67 per share and revenue of $4.57 billion for the quarter. Boston Scientific has set its Q1 2025 guidance at 0.660-0.680 EPS and its FY 2025 guidance at 2.800-2.870 EPS.Individual interested in registering for the company’s earnings conference call can do so using this link.

Boston Scientific (NYSE:BSX) last issued its earnings results on Wednesday, February 5th. The medical equipment provider reported $0.70 earnings per share for the quarter, beating analysts’ consensus estimates of $0.65 by $0.05. Boston Scientific had a return on equity of 17.80% and a net margin of 11.07%. On average, analysts expect Boston Scientific to post $3 EPS for the current fiscal year and $3 EPS for the next fiscal year.

Boston Scientific Stock Performance

BSX stock opened at $94.19 on Wednesday. The stock has a market cap of $139.32 billion, a P/E ratio of 75.35, a P/E/G ratio of 2.79 and a beta of 0.73. The company has a debt-to-equity ratio of 0.41, a quick ratio of 1.02 and a current ratio of 1.08. The firm has a 50 day simple moving average of $100.11 and a 200 day simple moving average of $94.18. Boston Scientific has a 52 week low of $66.80 and a 52 week high of $107.17.

Analyst Ratings Changes

A number of equities research analysts have issued reports on BSX shares. Argus set a $130.00 target price on shares of Boston Scientific in a research note on Tuesday, February 18th. StockNews.com downgraded shares of Boston Scientific from a “buy” rating to a “hold” rating in a research report on Saturday, March 8th. Raymond James raised their price target on shares of Boston Scientific from $119.00 to $122.00 and gave the company a “strong-buy” rating in a report on Thursday, February 6th. Stifel Nicolaus upped their price objective on shares of Boston Scientific from $100.00 to $115.00 and gave the stock a “buy” rating in a report on Thursday, February 6th. Finally, Truist Financial cut their target price on Boston Scientific from $120.00 to $113.00 and set a “buy” rating on the stock in a report on Friday, April 11th. Two research analysts have rated the stock with a hold rating, twenty-one have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $109.04.

Insiders Place Their Bets

In related news, EVP Arthur C. Butcher sold 17,313 shares of the stock in a transaction dated Monday, February 3rd. The shares were sold at an average price of $101.80, for a total value of $1,762,463.40. Following the completion of the transaction, the executive vice president now owns 5,502 shares of the company’s stock, valued at $560,103.60. This represents a 75.88 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, EVP John Bradley Sorenson sold 6,528 shares of the stock in a transaction that occurred on Friday, February 7th. The stock was sold at an average price of $104.97, for a total value of $685,244.16. Following the completion of the transaction, the executive vice president now directly owns 26,449 shares of the company’s stock, valued at approximately $2,776,351.53. The trade was a 19.80 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 133,183 shares of company stock worth $13,948,476 in the last ninety days. Insiders own 0.50% of the company’s stock.

Institutional Trading of Boston Scientific

A hedge fund recently raised its stake in Boston Scientific stock. Brighton Jones LLC lifted its position in Boston Scientific Co. (NYSE:BSX) by 0.8% during the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 27,376 shares of the medical equipment provider’s stock after purchasing an additional 226 shares during the quarter. Brighton Jones LLC’s holdings in Boston Scientific were worth $2,445,000 at the end of the most recent reporting period. 89.07% of the stock is owned by hedge funds and other institutional investors.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.